CRISPR Therapeutics CFO Buys Shares, Signaling Confidence in Upcoming Clinical & Regulatory Milestones
Insider trades reveal confidence in CRISPR Therapeutics’ gene‑editing platform; phase‑II oncology and rare‑disease data show high efficacy, low risk, and strong regulatory momentum.
4 minutes to read